Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 9 | 2022 | 267 | 1.780 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2019 | 9 | 0.750 |
Why?
|
| Vinca Alkaloids | 1 | 2014 | 3 | 0.470 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 22 | 0.460 |
Why?
|
| Folic Acid | 1 | 2014 | 123 | 0.440 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 1070 | 0.370 |
Why?
|
| Vaginal Neoplasms | 2 | 2016 | 21 | 0.250 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 349 | 0.230 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 848 | 0.190 |
Why?
|
| Autophagy | 2 | 2014 | 208 | 0.190 |
Why?
|
| Rib Fractures | 1 | 2021 | 37 | 0.190 |
Why?
|
| Accidents, Traffic | 1 | 2021 | 109 | 0.180 |
Why?
|
| Carcinoma | 2 | 2012 | 215 | 0.180 |
Why?
|
| Indazoles | 1 | 2019 | 12 | 0.170 |
Why?
|
| Female | 17 | 2022 | 38074 | 0.170 |
Why?
|
| Piperidines | 1 | 2019 | 123 | 0.160 |
Why?
|
| Lymph Nodes | 2 | 2017 | 258 | 0.160 |
Why?
|
| Hysterectomy | 1 | 2017 | 64 | 0.140 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 69 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2017 | 23 | 0.140 |
Why?
|
| Mesothelioma | 1 | 2017 | 21 | 0.140 |
Why?
|
| Quality of Life | 2 | 2022 | 1515 | 0.140 |
Why?
|
| Vulvar Neoplasms | 1 | 2016 | 24 | 0.130 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 99 | 0.130 |
Why?
|
| Folate Receptor 1 | 1 | 2014 | 2 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 378 | 0.120 |
Why?
|
| Papillomavirus Vaccines | 1 | 2016 | 93 | 0.120 |
Why?
|
| Humans | 17 | 2022 | 68618 | 0.120 |
Why?
|
| Vaccination | 1 | 2016 | 189 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 300 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 151 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 137 | 0.110 |
Why?
|
| CA-125 Antigen | 1 | 2012 | 5 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 170 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 468 | 0.100 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2011 | 4 | 0.100 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2012 | 37 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2011 | 137 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2016 | 7029 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2012 | 175 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 307 | 0.090 |
Why?
|
| Laparoscopy | 1 | 2012 | 237 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 434 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2019 | 714 | 0.090 |
Why?
|
| Proteins | 1 | 2012 | 474 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 508 | 0.080 |
Why?
|
| Prognosis | 3 | 2018 | 2093 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 951 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 4848 | 0.070 |
Why?
|
| Middle Aged | 7 | 2019 | 21147 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 369 | 0.060 |
Why?
|
| Apoptosis | 1 | 2011 | 1641 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2021 | 7277 | 0.060 |
Why?
|
| Smoking | 1 | 2012 | 1452 | 0.060 |
Why?
|
| Adult | 6 | 2019 | 21403 | 0.050 |
Why?
|
| Aged | 5 | 2019 | 14862 | 0.050 |
Why?
|
| Animals | 3 | 2014 | 20881 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 536 | 0.050 |
Why?
|
| Ribs | 1 | 2021 | 25 | 0.050 |
Why?
|
| Motor Vehicles | 1 | 2021 | 20 | 0.050 |
Why?
|
| Cell Survival | 2 | 2014 | 901 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 10 | 0.040 |
Why?
|
| Nausea | 1 | 2019 | 47 | 0.040 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2018 | 14 | 0.040 |
Why?
|
| Disease Progression | 1 | 2022 | 1038 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 411 | 0.040 |
Why?
|
| CD8 Antigens | 1 | 2017 | 25 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2017 | 41 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 94 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 91 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 1603 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 91 | 0.040 |
Why?
|
| Survival Rate | 1 | 2018 | 1056 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 2334 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1738 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 792 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 266 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 274 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 800 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1426 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 183 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2800 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2014 | 294 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 304 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2013 | 149 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2014 | 215 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 279 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2012 | 122 | 0.030 |
Why?
|
| Pulmonary Atelectasis | 1 | 2012 | 12 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2012 | 24 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 2012 | 38 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2011 | 11 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2011 | 38 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 41 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 281 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 122 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 127 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 272 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 100 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 563 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 282 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 254 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 200 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 114 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 223 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1174 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 770 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 447 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 1851 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 782 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 331 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 682 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1174 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 1465 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1046 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 756 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2011 | 617 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 1196 | 0.020 |
Why?
|
| United States | 1 | 2017 | 7367 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 1615 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 5731 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 2689 | 0.010 |
Why?
|
| Child | 1 | 2012 | 6405 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 5717 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 8474 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 8912 | 0.010 |
Why?
|